Related Experiment Video

Updated: Jul 11, 2025

Sequential Salt Extractions for the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes
07:41

Sequential Salt Extractions for the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes

Published on: October 2, 2017

8.4K

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy

Zhi-Qiang Wang1, Zhao-Cong Zhang1, Yu-Yang Wu2

  • 1Department of Gynecology Oncology, Harbin Medical University Cancer Hospital, Harbin, 150086, China.

Signal Transduction and Targeted Therapy
|November 5, 2023
PubMed

Insights

BET inhibitors show promise as epigenetic anticancer treatments, but limited effectiveness alone. Combining BET inhibitors with other drugs offers a promising strategy for enhanced cancer therapy.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • BET proteins function as epigenetic interpreters, regulating gene expression crucial in cancer development.
  • BET inhibitors represent a novel epigenetic approach to cancer treatment.
  • Preliminary clinical trials indicate anticancer potential but limited monotherapeutic efficacy.

Purpose of the Study:

  • To review the function of BET proteins and their targeting in cancer.
  • To examine advances in small-molecule BET inhibitors and clinical findings.
  • To explore combination strategies and resistance mechanisms for BET inhibitors.

Main Methods:

  • Literature review of BET protein function, cancer targeting, and inhibitor development.
  • Analysis of preclinical data and preliminary clinical trial results.
  • Investigation into resistance mechanisms, adverse events, and synergistic drug combinations.

Main Results:

  • BET inhibitors demonstrate anticancer potential but face challenges with monotherapy.
  • Understanding resistance mechanisms and adverse events is critical for effective use.
  • Numerous synergistic combinations with other agents are being explored.

Conclusions:

  • Combining BET inhibitors with other anticancer drugs and next-generation agents holds significant potential.
  • Optimizing combination therapies is key to advancing BET protein targeting in oncology.
  • BET inhibitors are a promising strategy for potent antitumor effects when used judiciously.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.2K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila00:06

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.8K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K